Delphine Lebon

870 total citations
42 papers, 243 citations indexed

About

Delphine Lebon is a scholar working on Hematology, Oncology and Genetics. According to data from OpenAlex, Delphine Lebon has authored 42 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 14 papers in Oncology and 12 papers in Genetics. Recurrent topics in Delphine Lebon's work include Acute Myeloid Leukemia Research (17 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Multiple Myeloma Research and Treatments (8 papers). Delphine Lebon is often cited by papers focused on Acute Myeloid Leukemia Research (17 papers), Hematopoietic Stem Cell Transplantation (12 papers) and Multiple Myeloma Research and Treatments (8 papers). Delphine Lebon collaborates with scholars based in France, United States and Belgium. Delphine Lebon's co-authors include Jean‐Pierre Marolleau, Loïc Garçon, Alexis Caulier, Hakim Ouled‐Haddou, Véronique Picard, Corinne Guitton, Jean‐Baptiste Micol, Sarah Bertoli, Jacques Rochette and Christian Récher and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Delphine Lebon

39 papers receiving 242 citations

Peers

Countries citing papers authored by Delphine Lebon

Since Specialization

Citations

This map shows the geographic impact of Delphine Lebon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Delphine Lebon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Delphine Lebon more than expected).

Fields of papers citing papers by Delphine Lebon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Delphine Lebon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Delphine Lebon. The network helps show where Delphine Lebon may publish in the future.

Co-authorship network of co-authors of Delphine Lebon

This figure shows the co-authorship network connecting the top 25 collaborators of Delphine Lebon. A scholar is included among the top collaborators of Delphine Lebon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Delphine Lebon. Delphine Lebon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Monitoring of measurable residual disease by next‐generation sequencing in patients with acute myeloid leukaemia 2025 ·British Journal of Haematology ·(unknown), (unknown), Delphine Lebon, (unknown), Véronique Harrivel, (unknown), (unknown), Alice Marceau‐Renaut, Sandrine Geffroy, (unknown), (unknown), Laurène Fenwarth, Céline Berthon, Jean‐Pierre Marolleau, Martin Figeac, Claude Preudhomme, Nicolas Duployez	1
2	Efficacy and safety of pivekimab sunirine (PVEK) in patients (pts) with blastic plasmacytoid dendritic cell neoplasm (BPDCN) in the CADENZA study. 2025 ·Journal of Clinical Oncology ·Naveen Pemmaraju, Giovanni Marconi, Pau Montesinos, Andrew A. Lane, Luca Mazzarella, David A. Sallman, Matthew L. Ulrickson, Gary J. Schiller, Harry P. Erba, Eunice S. Wang, Roland B. Walter, Éric Deconinck, Ahmed Aribi, Ollivier Legrand, Delphine Lebon, Giovanni Martinelli, Daniel J. DeAngelo, (unknown), Jalaja Potluri, Naval Daver	1
3	PIEZO1 is essential for the survival and proliferation of acute myeloid leukemia cells 2024 ·Cancer Medicine ·Delphine Lebon, (unknown), (unknown), Cathy Gomila, Hakim Ouled‐Haddou, (unknown), Yohann Demont, Jean‐Pierre Marolleau, Alexis Caulier, Loïc Garçon	2
4	STIM2 is involved in the regulation of apoptosis and the cell cycle in normal and malignant monocytic cells 2024 ·Molecular Oncology ·(unknown), Raphaël Itzykson, Frédéric Hague, Delphine Lebon, Julien M. D. Legrand, Hakim Ouled‐Haddou, Guillaume Jedraszak, (unknown), (unknown), Étienne Paubelle, Jean‐Pierre Marolleau, Loïc Garçon, Thomas Boyer	3
5	A retrospective comparison of abbreviated course “7+7” vs standard hypomethylating agent plus venetoclax doublets in older/unfit patients with newly diagnosed acute myeloid leukemia. 2024 ·Journal of Clinical Oncology ·Alexandre Bazinet, Courtney D. DiNardo, (unknown), Álex Bataller, Caitlin R. Rausch, Abhishek Maiti, Mahesh Swaminathan, Naval Daver, Tapan M. Kadia, Farhad Ravandi, Hagop M. Kantarjian, (unknown), Justine Decroocq, Laurent Pascal, Delphine Lebon, Sarah Bonnet, Nicolas Gauthier, Arnaud Pagès, Stéphane de Botton, Christophe Willekens	7
6	Platelet transfusions in haploidentical haematopoietic stem cell allograft candidates: Protecting HLA‐A and HLA‐B antigens through eplet analysis 2024 ·HLA ·G Durand, (unknown), (unknown), (unknown), Magalie Joris, A Charbonnier, Delphine Lebon, Étienne Paubelle, Loïc Garçon, Nicolas Guillaume	1
7	French Retrospective Database Analysis of Patient Characteristics and Treatment Patterns in Patients with R/R FLT3-Mutated AML: A Registry-Based Cohort Study 2023 ·Oncology and Therapy ·(unknown), (unknown), Céline Berthon, Delphine Lebon, (unknown), (unknown), (unknown), (unknown)	0
8	Effect of single-unit transfusion in patients treated for haematological disease including acute leukemia: A multicenter randomized controlled clinical trial 2023 ·Leukemia Research ·(unknown), (unknown), (unknown), (unknown), (unknown), S. Chèze, Stéphane Girault, Pascal Turlure, JP Marolleau, Delphine Lebon, A Charbonnier, Fabrice Jardin, Pascal Lenain, (unknown), (unknown), (unknown), (unknown), (unknown), Oumédaly Reman, (unknown)	6
9	Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03) 2023 ·SHILAP Revista de lepidopterología ·Zoé Van de Wyngaert, Florent Malard, Cyrille Hulin, Denis Caillot, Clara Mariette, Thierry Façon, Cyrille Touzeau, Aurore Perrot, Philippe Moreau, Benjamin Hébraud, Tarik Kanouni, Farhad Heshmati, Delphine Lebon, Mohamad Mohty, Christian Chabannon	1
10	Impressive extramedullary plasmacytoma response in refractory multiple myeloma treated with teclistamab 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), (unknown), Delphine Lebon, (unknown)	1
11	The Occurrence of Infection and TP53 Mutation Are Risk Factors for Cardiovascular Toxicity of Acute Myeloid Leukemia Induction Therapy 2023 ·Blood ·(unknown), Laurène Fenwarth, Delphine Lebon, Nicolas Duployez, (unknown), Magalie Joris, A Charbonnier, (unknown), Claude Preudhomme, Christophe Tribouilloy, Jean Pierre Marolleau, Pierre Morel	1
12	Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease 2022 ·Leukemia Research ·Delphine Lebon, (unknown), Alexis Caulier, Magalie Joris, A Charbonnier, Bérengère Gruson, (unknown), Sandrine Castelain, Catherine François, (unknown), Nicolas Guillaume, Jean‐Pierre Marolleau, P. Morel	3
13	Utility of assessing CD3⁺ cell chimerism within the first months after allogeneic hematopoietic stem‐cell transplantation for acute myeloid leukemia 2022 ·HLA ·(unknown), (unknown), Pascaline Etancelin, Zuzana Saidak, Delphine Lebon, Loïc Garçon, Jean‐Pierre Marolleau, (unknown), Nicolas Guillaume	5
14	Final Long-Term Results from the Defifrance Registry Study: Efficacy and Safety of Defibrotide for the Treatment of Severe/Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation 2021 ·Blood ·Mohamad Mohty, Didier Blaise, Régis Peffault de Latour, Myriam Labopin, Marie Y. Detrait, Stéphane Girault, Anne Huynh, Hélène Labussière‐Wallet, Thierry Lamy, Delphine Lebon, Sébastien Maury, C. Rénard, Kobby Asubonteng, (unknown), Ibrahim Yakoub‐Agha, Jean‐Hugues Dalle	0
15	Intérêt des biopsies œsophagiennes au cours de la maladie du greffon contre l’hôte 2021 ·Annales de Pathologie ·(unknown), (unknown), Delphine Lebon, Mathurin Fuméry, (unknown), Denis Chatelain	1
16	Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia 2020 ·Blood ·Eytan M. Stein, Stéphane de Botton, Thomas Cluzeau, Arnaud Pigneux, Jane L. Liesveld, Rachel J. Cook, Philippe Rousselot, David A. Rizzieri, Thorsten Braun, Dale L. Bixby, Gail J. Roboz, Delphine Lebon, Maël Heiblig, Michael Kelly, Angela Volkert, Li Zhou, (unknown), David A. Roth, Pierre Péterlin	2
17	PIEZO1 activation delays erythroid differentiation of normal and hereditary xerocytosis-derived human progenitor cells 2019 ·Haematologica ·Alexis Caulier, (unknown), Yohann Demont, Hakim Ouled‐Haddou, (unknown), Corinne Guitton, (unknown), Delphine Lebon, (unknown), (unknown), Agnès Lahary, Christian Rosé, (unknown), (unknown), (unknown), Halima Ouadid‐Ahidouch, Jacques Rochette, Jean‐Pierre Marolleau, Véronique Picard, Loïc Garçon	47
18	Gastrointestinal emergencies in critically ill cancer patients 2017 ·Journal of Critical Care ·Delphine Lebon, Lucie Biard, Sophie Buyse, David Schnell, Étienne Lengliné, Camille Roussel, Jean‐Marc Gornet, Nicolas Munoz‐Bongrand, L. Quéro, Matthieu Resche‐Rigon, Élie Azoulay, Emmanuel Canet	11
19	Hyperferritinemia at diagnosis predicts relapse and overall survival in younger AML patients with intermediate-risk cytogenetics 2015 ·Leukemia Research ·Delphine Lebon, François Vergez, Sarah Bertoli, Véronique Harrivel, Stéphane de Botton, Jean‐Baptiste Micol, Jean‐Pierre Marolleau, Christian Récher	29
20	Patella plasmacytoma: An unusual localization 2010 ·American Journal of Hematology ·Delphine Lebon, (unknown), (unknown), (unknown), Bruno Royer	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact